This article first appeared on GuruFocus .
-
Net Product Revenue:$18.6 million in Q2 2026, compared to $18.1 million in Q2 2025.
-
Product Sales:$2.3 million for Q2 2026 and $6 million for the six months ended June 30, 2026, versus $0.8 million and $2.9 million in the same periods of 2025.
-
Total Operating Expenses:$44.7 million for Q2 2026; adjusted operating expenses were $37.2 million, down 22% year-over-year.
-
Net Loss (GAAP):$16.6 million for Q2 2026, compared to a net loss of $56.6 million in Q2 2025.
-
Adjusted Net Loss (non-GAAP):$16.3 million for Q2 2026, versus a net loss of $28.7 million in Q2 2025.
-
Cash Position:$219.1 million in cash equivalents as of June 30, 2026, compared to $231 million as of March 31, 2026.
-
Cost Savings:Approximately $10 million in annualized savings from a strategic reorganization, including a 17% workforce reduction.
Release Date: August 13, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
ADC Therapeutics SA ( NYSE:ADCT ) reported Q2 2026 net product revenues of $18.6 million, slightly up from $18.1 million in Q2 2025, indicating stable commercial performance for Zynlonta in third-line plus DLBCL.
-
The company completed enrollment of 100 patients in the LOTUS-7 trial, with data suggesting the Zynlonta plus glofitamab combination is the most compelling in second-line DLBCL, potentially positioning it as a best-in-class therapy.
-
ADC Therapeutics SA ( NYSE:ADCT ) plans to submit for breakthrough therapy designation for the LOTUS-7 combination and is exploring a Phase 3 pathway, which could expand Zynlonta's use into earlier lines of therapy.
-
The company reduced operating expenses by 22% year-over-year on an adjusted basis and implemented a strategic reorganization expected to save approximately $10 million annually, improving financial efficiency.
-
ADC Therapeutics SA ( NYSE:ADCT ) ended Q2 2026 with a healthy cash balance of $219.1 million, providing a cash runway at least into 2028 to support key clinical and regulatory activities.
-
The company is advancing multiple pipeline opportunities, including updated data for marginal zone lymphoma and follicular lymphoma, with potential for breakthrough designation in MZL, broadening Zynlonta's addressable market.
Negative Points
-
The FDA expressed substantial concerns regarding the benefit-risk profile of the LOTUS-5 trial, which met its primary endpoint of progression-free survival, casting uncertainty on the regulatory path for full approval of Zynlonta plus rituximab.
-
ADC Therapeutics SA ( NYSE:ADCT ) is reassessing the regulatory strategy for LOTUS-5, with no clear timeline for resolution, potentially delaying label expansion into second-line DLBCL.
-
The LOTUS-5 trial observed grade 5 infections, primarily bacterial, which were not mitigated by prophylaxis, raising safety concerns that could impact the drug's perception and adoption.
-
The company's strategic reorganization included a 17% workforce reduction, which may affect operational capacity and morale, despite cost savings.
-
ADC Therapeutics SA ( NYSE:ADCT ) faces a competitive and evolving DLBCL landscape, and the delay in LOTUS-5 regulatory progress could allow competitors to gain market share in earlier lines of therapy.
-
The company's net loss, while improved, remains significant at $16.6 million for Q2 2026, and the reliance on pipeline success for future growth carries inherent clinical and regulatory risks.
Q & A Highlights
Q: Given the FDA's concerns regarding the benefit-risk profile of the LOTUS-5 trial, was there any discussion about maintaining the current accelerated approval status for Zynlonta? A: Ameet Mallik, CEO, clarified that the FDA's feedback was specific to the LOTUS-5 trial combination of loncastuximab tesirine plus rituximab, not the single-agent therapy. He confirmed the company remains confident that the monotherapy will stay on the market with its accelerated approval and is committed to working with the FDA to satisfy full approval requirements, either through LOTUS-5 or another study.
Q: Have you seen the final ASH presentation data for LOTUS-7, and do your comments about compelling efficacy and consistent safety pertain to that final dataset? A: Ameet Mallik, CEO, confirmed that the abstract submitted for ASH contains the vast majority of the 100 enrolled patients. He stated that the belief in the compelling efficacy and safety data is reflective of that abstract, though he could not share all details due to disclosure reasons.
Q: Regarding the exploration of a Phase 3 pathway for the LOTUS-7 combination, is this being pursued with Roche or independently? A: Ameet Mallik, CEO, declined to comment on specifics but noted the strong partnership with Roche. He stated the company has been preparing different design options for a potential Phase 3 trial, plans to file for breakthrough designation this year, and will discuss the path forward with the FDA.
Q: Can you provide more detail on the type of grade 5 infections observed in LOTUS-5, and would they have been mitigated by the prophylactic and vaccination strategies now incorporated in LOTUS-7? A: Ameet Mallik, CEO, stated that the primary type of infections were bacterial, which is why the company believes prophylaxis could play a role. He emphasized the significant protocol differences between LOTUS-5 and LOTUS-7, with the latter recommending prophylaxis including vaccinations for viral, fungal, and bacterial infections.
Q: How do you think about the potential read-through from the LOTUS-5 grade 5 signal to potential NCCN Compendia inclusion and adoption of the Zynlonta plus glofitamab combination? A: Ameet Mallik, CEO, stated there is no read-through between LOTUS-5 and Compendia inclusion as they are two very different studies with different regimens and protocols. He referenced prior disclosures showing a low percentage of grade 5 events (approximately 4%) in the LOTUS-7 data from December, indicating a difference between the studies.
Q: Did the FDA provide any indication of what an effective path forward might look like for the Phase 3, and what strategies are you considering? A: Ameet Mallik, CEO, explained that during the pre-sBLA meeting, the FDA shared concerns typical of such meetings. The company is now assessing whether additional data, risk management options, or modifications to the potential label can address the FDA's concerns, which forms the basis of evaluating the path forward for LOTUS-5.
Q: Did you see any changes in patient starts, unit demand, dosing, or physician prescribing behaviors following the LOTUS-5 disclosure? Also, did the FDA focus on PFS in patients 75 or older? A: Ameet Mallik, CEO, confirmed that Q2 sales were consistent with prior quarters with no impact from the disclosure, as the monotherapy has an established place in the third-line plus DLBCL setting. He noted that older patients with infections may benefit from prophylaxis, but emphasized that each study is independent and there is no read-through from LOTUS-5 to other studies or the current indication.
Q: Can you provide any color on the timeline for the Phase 3 plans for LOTUS-7, given it appears to be more of a future focus? A: Ameet Mallik, CEO, stated it is premature to discuss timing and cost while still gathering input from the medical community and collaborating with the FDA on a final design. He emphasized that the company is pursuing the LOTUS-5 regulatory path and the LOTUS-7 breakthrough designation and Phase 3 exploration in parallel.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
